Yanbian Prefecture, Jilin Province, Held a Training Session for Health Care Workers From Nov. 30th to Dec. 2nd, 2018, the China Hepatitis C Elimination Alliance Public Welfare Project team held a three-day training session for 300 health care workers from Jilin province and nationwide in Yanbian University Hospital in Yanji City, Yanbian Korean Autonomous Prefecture, Jilin Province.
Group photo of experts and trainees The event was co-hosted by China Liver Health, Yanbian University Hospital and Jilin Pharmaceutical Association. Prof. You Hong from Beijing Friendship Hospital, Vice President Liu Bin of the First Bethune Hospital of Jilin University, Prof. Xiong Yuqing (also the honorary chairman) from Drug Clinical Trial Professional Committee of Chinese Pharmacological Society, Prof. Piao Hongxin from Yanbian University Hospital and other well-known experts from the industry were invited to deliver a lecture. The course covered the detection and treatment of hepatitis C, the application of direct-acting antivirals (DAAs) for hepatitis C, process management and risk control for drug clinical trials.
At the training session
Welcome speech by Secretary Liu Yanxiang of Yanbian University Hospital
Prof. You Hong from Beijing Friendship Hospital introduced the treatment plan for hepatitis C with DAAs According to Director Li Mingyang of China Liver Health, the China Hepatitis C Elimination Alliance Public Welfare Project was launched on Sep. 3rd, 2017 at the Great Hall of the People in Beijing, led by Academician Zhuang Hui (a well-known liver disease expert, professor from Peking University Health Science Center, and honorary chairman of China Liver Health) and Prof. Wei Lai (the sixth chairman of the Chinese Medical Association, director of Liver Diseases Institute of Peking University, and the president of China Liver Health). The project received guidance from the World Health Organization, the Ministry of Civil Affairs, the Department of Disease Control under National Health Commission and Chinese Center for Disease Control and Prevention and also received active cooperation and support from local governments. Up to November 2018, the project has carried out over 10 rounds of dialogues on including hepatitis C drugs into medical insurance list in Shaanxi, Anhui, Jilin, Hunan, Fujian and other provinces, trained over 1,200 liver disease doctors from primary health care institutions and conducted screening for hepatitis C infection for 6252 people. It greatly enhanced basic-level governments’ understanding, attention and confidence in eliminating hepatitis C, improved the willingness of the public, especially those high risk groups, to actively receive detection and treatment, and improved diagnosis and treatment level of liver disease doctors at primary health care institutions.
Director Li Mingyang introduced the China Hepatitis C Elimination Alliance Public Welfare Project Director Li said that oral DAAs for hepatitis C had been included into local medical insurance list in different ways in Zhejiang, Jilin, Tianjin, Anhui, Shandong and other provinces and cities. As this policy took root in more provinces and cities, there was hope that those 10 million people infected with hepatitis C virus in China would be completely cured and bear a smaller burden. Background Information Viral hepatitis C, hepatitis C for short, is a disease transmitted through blood and sexual contact, which can progress into serious diseases such as liver fibrosis, cirrhosis, liver cancer, etc., causing a serious disease burden to society and families. Hepatitis C can be completely cured by oral DAAs. In China, there are 10 million people infected with hepatitis C virus. Most of them have not been tested and effectively treated due to the insidious onset, insufficient attention from patients and high expenses of drugs. The China Hepatitis C Elimination Alliance Public Welfare Project is sponsored by China Liver Health and supported by Infectious Disease Institute of Peking University, Chinese Foundation of Hepatitis Prevention and Control, Liver Disease Institute of Peking University, Chinese Society of Hepatology under Chinese Medical Association, Chinese Society of Infectious Diseases under Chinese Medical Association, Jilin Institute of Liver Disease, the Virtual Community of Hepatitis C and Health Times of People’s Daily. It aims to promote the diagnosis and treatment of hepatitis C, better implement the Viral Hepatitis Prevention and Control Plan of China (2017-2020) and cooperate with World Health Organization to reach the strategic goal of eliminating hepatitis as a major public health threatm by 2030. |
关注官方微信 
